Concerns about potential impacts of GLP-1 drugs on the deman...
Concerns about potential impacts of GLP-1 drugs on the demand for diabetes device therapies may be misplaced, as illustrated by strong Q3 results from diabetes tech leaders like Abbott, Dexcom, and Insulet.
Heard on the Street: The Ozempic Clouds Are Parting for Medical Device Makers -- WSJ
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment